Cohort study of the association of antibody levels to AMA1, MSP1 19, MSP3 and GLURP with protection from clinical malaria in Ghanaian children

Malaria Journal

Volumn 7, Issue , 2008, Pages

  Dodoo, Daniel ^a   Aikins, Anastasia ^a   Kusi, Kwadwo Asamoah ^a,b   Lamptey, Helena ^a   Remarque, Ed ^b   Milligan, Paul ^c   Bosomprah, Samuel ^d   Chilengi, Roma ^e   Osei, Yaa Difie ^f   Akanmori, Bartholomew Dicky ^a   Theisen, Michael ^g  

^a University of Ghana   (Ghana)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d MINISTRY OF HEALTH   (Ghana)

^e African Malaria Network Trust   (Tanzania)

^f UNIVERSITY OF GHANA   (Ghana)

^g STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; GLUTAMATE RICH PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 3; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; GLUTAMATE RICH PROTEIN, PLASMODIUM; GLUTAMATE-RICH PROTEIN, PLASMODIUM; IMMUNOGLOBULIN CLASS; MSP3 PROTEIN, PLASMODIUM FALCIPARUM (181 276); MSP3 PROTEIN, PLASMODIUM FALCIPARUM (181-276); PARASITE ANTIGEN; PEPTIDE FRAGMENT; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GHANA; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALARIA; MALE; STATISTICAL SIGNIFICANCE; ANIMAL; BLOOD; IMMUNOLOGY; MALARIA FALCIPARUM; PRESCHOOL CHILD;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GHANA; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; MALARIA, FALCIPARUM; MALE; MEROZOITE SURFACE PROTEIN 1; PEPTIDE FRAGMENTS; PROTOZOAN PROTEINS;

EID: 51249114470     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-7-142     Document Type: Article

References (56)

1. Gamma-globulin and acquired immunity to human malaria. S Cohen IA McGREGOR S CARRINGTON, Nature 1961 192 733 737 10.1038/192733a0 13880318
2. Serum antibody in acquired malarial immunity. S Cohen GA Butcher, Trans R Soc Trop Med Hyg 1971 65 125 135 10.1016/0035-9203(71)90210-0 4934028
3. Towards the development of the ideal malaria vaccine. A decade of progress in a difficult field. MF Good, Med J Aust 1991 154 284 289 1994206
4. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. A Sabchareon T Burnouf D Ouattara P Attanath H Bouharoun-Tayoun P Chantavanich C Foucault T Chongsuphajaisiddhi P Druilhe, Am J Trop Med Hyg 1991 45 297 308 1928564
5. Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region. EM Braga RM Barros TA Reis CJ Fontes CG Morais MS Martins AU Krettli, Am J Trop Med Hyg 2002 66 461 466 12201577
6. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. D Dodoo TG Theander JA Kurtzhals K Koram E Riley BD Akanmori FK Nkrumah L Hviid, Infect Immun 1999 67 2131 2137 10225865
7. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. AF Egan J Morris G Barnish S Allen BM Greenwood DC Kaslow AA Holder EM Riley, J Infect Dis 1996 173 765 769 8627050
8. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. S Soe M Theisen C Roussilhon KS Aye P Druilhe, Infect Immun 2004 72 247 252 14688102 10.1128/IAI.72.1.247-252.2004
9. Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission. JP Lusingu LS Vestergaard M Alifrangis BP Mmbando M Theisen AY Kitua MM Lemnge TG Theander, Malar J 2005 4 48 16194274 10.1186/1475-2875-4-48
10. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. I Nebie A Diarra A Ouedraogo I Soulama EC Bougouma AB Tiono AT Konate R Chilengi M Theisen D Dodoo E Remarque S Bosomprah P Milligan SB Sirima, Infect Immun 2008 76 759 766 18070896 10.1128/IAI.01147-07
11. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. SB Sirima I Nebie A Ouedraogo AB Tiono AT Konate A Gansane AI Derme A Diarra A Ouedraogo I Soulama N Cuzzin-Ouattara S Cousens O Leroy, Vaccine 2007 25 2723 2732 10.1016/j.vaccine.2006.05.090 17280744
12. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. V Meraldi I Nebie AB Tiono D Diallo E Sanogo M Theisen P Druilhe G Corradin R Moret BS Sirima, Parasite Immunol 2004 26 265 272 10.1111/j.0141-9838.2004.00705.x 15541030
13. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes. G Hui C Hashimoto, Vaccine 2007 25 948 956 10.1016/j.vaccine.2006.08.041 17023096
14. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. SD Polley T Mwangi CH Kocken AW Thomas S Dutta DE Lanar E Remarque A Ross TN Williams G Mwambingu B Lowe DJ Conway K Marsh, Vaccine 2004 23 718 728 10.1016/j.vaccine.2004.05.031 15542195
15. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. H Bouharoun-Tayoun C Oeuvray F Lunel P Druilhe, J Exp Med 1995 182 409 418 7629503 10.1084/jem.182.2.409
16. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. CC Hermsen DF Verhage DS Telgt K Teelen JT Bousema M Roestenberg A Bolad K Berzins G Corradin O Leroy M Theisen RW Sauerwein, Vaccine 2007 25 2930 2940 10.1016/j.vaccine.2006.06.081 16914240
17. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized. K Miura H Zhou OV Muratova AC Orcutt B Giersing LH Miller CA Long, Infect Immun 2007 75 5827 5836 17923516 10.1128/IAI.00593-07
18. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. M Theisen S Soe C Oeuvray AW Thomas J Vuust S Danielsen S Jepsen P Druilhe, Infect Immun 1998 66 11 17 9423833
19. Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. MJ Blackman AA Holder, Mol Biochem Parasitol 1992 50 307 315 10.1016/0166-6851(92)90228-C 1741018
20. Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate lifecycle. MB Borre M Dziegiel B Høgh E Petersen K Rieneck E Riley JF Meis M Aikawa K Nakamura M Harada etc, Mol Biochem Parasitol 1991 49 119 132 10.1016/0166-6851(91)90135-S 1775153
21. A malaria merozoite surface protein (MSP1)-structure, processing and function. AA Holder MJ Blackman PA Burghaus JA Chappel IT Ling N McCallum-Deighton S Shai, Mem Inst Oswaldo Cruz 1992 87 Suppl 3 37 42 1343716
22. Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro. F Lunel P Druilhe, Infect Immun 1989 57 2043 2049 2659533
23. Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. GH Mitchell AW Thomas G Margos AR Dluzewski LH Bannister, Infect Immun 2004 72 154 158 14688092 10.1128/IAI.72.1.154-158.2004
24. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. DL Narum AW Thomas, Mol Biochem Parasitol 1994 67 59 68 10.1016/0166-6851(94)90096- 5 7838184
25. Functional conservation of the malaria vaccine antigen MSP-119across distantly related Plasmodium species. RA O'Donnell A Saul AF Cowman BS Crabb, Nat Med 2000 6 91 95 10.1038/71595 10613831
26. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. C Oeuvray H Bouharoun-Tayoun H Gras-Masse E Bottius T Kaidoh M Aikawa MC Filgueira A Tartar P Druilhe, Blood 1994 84 1594 1602 8068948
27. Malaria-related beliefs and behaviour in southern Ghana: implications for treatment, prevention and control. CK Ahorlu SK Dunyo EA Afari KA Koram FK Nkrumah, Trop Med Int Health 1997 2 488 499 10.1046/j.1365-3156.1997.d01-298.x 9217705
28. Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. DR Cavanagh D Dodoo L Hviid JA Kurtzhals TG Theander BD Akanmori S Polley DJ Conway K Koram JS McBride, Infect Immun 2004 72 6492 6502 15501780 10.1128/IAI.72.11.6492-6502.2004
29. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. D Dodoo M Theisen JA Kurtzhals BD Akanmori KA Koram S Jepsen FK Nkrumah TG Theander L Hviid, J Infect Dis 2000 181 1202 1205 10.1086/315341 10720556
30. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. M Theisen D Dodoo A Toure-Balde S Soe G Corradin KK Koram JA Kurtzhals L Hviid T Theander B Akanmori M Ndiaye P Druilhe, Infect Immun 2001 69 5223 5229 11500389 10.1128/IAI.69.9.5223-5229.2001
31. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. CH Kocken C Withers-Martinez MA Dubbeld WA van der F Hackett A Valderrama MJ Blackman AW Thomas, Infect Immun 2002 70 4471 4476 12117958 10.1128/IAI.70.8.4471-4476.2002
32. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. M Theisen J Vuust A Gottschau S Jepsen B Hogh, Clin Diagn Lab Immunol 1995 2 30 34 7719909
33. Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate. S Bonnet S Petres I Holm T Fontaine S Rosario C Roth S Longacre, Vaccine 2006 24 5997 6008 10.1016/j.vaccine.2006.04.069 16814434
34. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. R Audran M Cachat F Lurati S Soe O Leroy G Corradin P Druilhe F Spertini, Infect Immun 2005 73 8017 8026 16299295 10.1128/IAI.73.12.8017-8026.2005
35. What is clinical malaria? Finding case definitions for field research in highly endemic areas. JR Schellenberg T Smith PL Alonso RJ Hayes, Parasitol Today 1994 10 439 442 10.1016/0169-4758(94)90179-1 15275531
36. Attributable fraction estimates and case definitions for malaria in endemic areas. T Smith JA Schellenberg R Hayes, Stat Med 1994 13 2345 2358 10.1002/sim.4780132206 7855468
37. A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. DR Cavanagh IM Elhassan C Roper VJ Robinson H Giha AA Holder L Hviid TG Theander DE Arnot JS McBride, J Immunol 1998 161 347 359 9647243
38. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. C Oeuvray M Theisen C Rogier JF Trape S Jepsen P Druilhe, Infect Immun 2000 68 2617 2620 10768952 10.1128/IAI.68.5.2617-2620.2000
39. High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children. B Okech G Mujuzi A Ogwal H Shirai T Horii TG Egwang, Am J Trop Med Hyg 2006 74 191 197 16474069
40. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. BA Okech PH Corran J Todd A Joynson-Hicks C Uthaipibull TG Egwang AA Holder EM Riley, Infect Immun 2004 72 1557 1567 14977962 10.1128/IAI.72.3.1557-1567.2004
41. Seasonal characteristics of malaria infection in under-five children of a rural community in southern Ghana. EA Afari T Nakano F Binka S Owusu-Agyei J Asigbee, West Afr J Med 1993 12 39 42 8512880
42. Malaria infection, morbidity and transmission in two ecological zones Southern Ghana. EA Afari M Appawu S Dunyo A Baffoe-Wilmot FK Nkrumah, Afr J Health Sci 1995 2 312 315 12160443
43. Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. D Dodoo T Staalsoe H Giha JA Kurtzhals BD Akanmori K Koram S Dunyo FK Nkrumah L Hviid TG Theander, Infect Immun 2001 69 3713 3718 11349035 10.1128/IAI.69.6.3713-3718. 2001
44. Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. JE Tongren CJ Drakeley SL McDonald HG Reyburn A Manjurano WM Nkya MM Lemnge CD Gowda JE Todd PH Corran EM Riley, Infect Immun 2006 74 257 264 16368979 10.1128/IAI.74.1.257-264.2006
45. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. JK Baird, Parasitol Today 1995 11 105 111 10.1016/0169-4758(95) 80167-7 15275362
46. Possible role of specific immunoglobulin M antibodies to Plasmodium falciparum antigens in immunoprotection of humans living in a hyperendemic area, Burkina Faso. C Boudin B Chumpitazi M Dziegiel F Peyron S Picot B Hogh P Ambroise-Thomas, J Clin Microbiol 1993 31 636 641 8458956
47. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. OH Branch V Udhayakumar AW Hightower AJ Oloo WA Hawley BL Nahlen PB Bloland DC Kaslow AA Lal, Am J Trop Med Hyg 1998 58 211 219 9502606
48. Anti-merozoite surface protein-1 19-kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay Cohort Project. OH Branch AJ Oloo BL Nahlen D Kaslow AA Lal, J Infect Dis 2000 181 1746 1752 10.1086/315424 10823777
49. IgG isotype to C-terminal 19 kDa of Plasmodium vivax merozoite surface protein 1 among subjects with different levels of exposure to malaria in Brazil. CG Morais IS Soares LH Carvalho CJ Fontes AU Krettli EM Braga, Parasitol Res 2005 95 420 426 10.1007/s00436-005-1314-x 15759156
50. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. H Bouharoun-Tayoun P Druilhe, Infect Immun 1992 60 1473 1481 1548071
51. Antibodies in falciparum malaria: what matters most, quantity or quality? H Bouharoun-Tayoun P Druilhe, Mem Inst Oswaldo Cruz 1992 87 Suppl 3 229 234 1343695
52. Fc gamma receptor IIa (CD32) polymorphism and antibody responses to asexual blood-stage antigens of Plasmodium falciparum malaria in Sudanese patients. A Nasr NC Iriemenam M Troye-Blomberg HA Giha HA Balogun OF Osman SM Montgomery G ElGhazali K Berzins, Scand J Immunol 2007 66 87 96 10.1111/j.1365-3083.2007.01947.x 17587350
53. Polymorphism of the Fc gamma receptor IIA and malaria morbidity. EM Braga KKG Scopel NT Komatsu M daSilva-Nunes MU Ferreira, Journal of Molecular and Genetic Medicine 2005 1 5 10
54. Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria. A Aubouy F Migot-Nabias P Deloron, Infect Genet Evol 2007 7 147 154 10.1016/j.meegid.2006.07.001 16890498
55. The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. PH Corran RA O'Donnell J Todd C Uthaipibull AA Holder BS Crabb EM Riley, Infect Immun 2004 72 6185 6189 15385530 10.1128/IAI.72.10.6185-6189.2004
56. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. C Uthaipibull B Aufiero SE Syed B Hansen JA Guevara Patino E Angov IT Ling K Fegeding WD Morgan C Ockenhouse B Birdsall J Feeney JA Lyon AA Holder, J Mol Biol 2001 307 1381 1394 10.1006/jmbi.2001.4574 11292349